CapsoVision wins FDA clearance for AI Highlights capsule endoscopy tool

CapsoVision's AI-assisted reading tool for its CapsoCam Plus system has received FDA clearance, following an earlier EU launch under MDR.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A monitor displaying a glowing green and blue circuit-like pattern sits on a mobile cart in a brightly lit, modern medical or tech facility with other equipment in the background.

CapsoVision has received FDA clearance for AI Highlights, its artificial intelligence-assisted reading tool for the CapsoCam Plus capsule endoscopy system. The clearance, granted on 25 September 2026, covers use in adult and paediatric patients aged over two years undergoing small bowel studies where suspected bleeding is the clinical indication.

The tool is designed to reduce the time physicians spend reviewing capsule endoscopy footage. It does so by analysing video frames captured by the CapsoCam Plus device, identifying images that contain suspected abnormal lesions, and surfacing those frames as prioritised highlights for physician review. AI Highlights integrates directly with CapsoVision's CapsoView software and its CapsoCloud platform, allowing processed studies to be accessed remotely for review and case collaboration without requiring a separate AI infrastructure.

Regulatory and product context

The US clearance follows an international rollout that included approval under the EU Medical Device Regulation earlier in 2026. Johnny Wang, President and Chief Executive Officer of CapsoVision, said the milestone reflects the company's commitment to "bringing integrated, AI-assisted technologies to physicians in the United States" and expressed confidence that the tools "may help support physician efficiency and may help improve reading performance" as the capsule endoscopy market continues to grow. CapsoVision was careful to note that AI Highlights is intended as a support tool for trained healthcare professionals and is not a replacement for gastroenterologists' diagnostic judgement.

The company's pipeline includes CapsoCam Colon, a next-generation device with enhanced AI designed for non-invasive colon imaging and polyp detection. CapsoVision has also indicated a longer-term ambition to extend its platform across additional gastrointestinal indications, including oesophageal and pancreatic disorders.

Market landscape

The capsule endoscopy market is increasingly competitive, with AI-assisted reading becoming a differentiating factor among device makers. Medtronic's PillCam platform remains the dominant global brand by installed base, while a number of smaller companies and academic spinouts have developed AI triage layers aimed at reducing the reading burden that has historically limited wider clinical adoption of capsule-based diagnostics. Regulatory momentum is broadly supportive: the FDA has cleared several AI-based software tools for gastrointestinal applications in recent years under its Software as a Medical Device framework, and the EU's MDR pathway for AI-enabled devices, while more demanding than its predecessor, has not materially slowed approvals for well-validated algorithms.

For CapsoVision, the practical significance of the US clearance is commercial access to the world's largest medical device market at a point when endoscopy capacity constraints and workforce pressures are pushing health systems to look harder at efficiency technologies. Whether AI Highlights translates into accelerated CapsoCam Plus adoption will depend on how reimbursement frameworks evolve and on the company's ability to demonstrate measurable improvements in reading time and diagnostic yield in real-world settings.

Sector

Topic

Geography